Table 1 Patient characteristics and pain mechanisms on the day of CSCI initiation
Total cohort | Main study group, ≥ 3 days of survival | |||
|---|---|---|---|---|
Total | Methadone in CSCI | No methadone in CSCI | ||
n = 93 | n = 47 | n = 13 | n = 34 | |
Females n (%) | 53 (57) | 25 (53) | 5 (38) | 19 (56) |
Age years | ||||
mean (SD) | 76.3 (10.6) | 75.6 (12.1) | 68.7 (11.7) | 78.2 (11.5)* |
median (IQR) | 77 (12) | 76 (16) | 71 (14.5) | 77.5 (16.3) |
Survival days | ||||
mean (SD)a | 8 (10) | 9 (9) | 13 (8) | 8 (10)* |
median (IQR) | 4 (5) | 5 (9) | 14 (14) | 4 (5) |
Midazolam | ||||
used midazolam n (%) | 63 (68) | 30 (64) | 7 (54) | 23 (68) |
Dose, mg/24 h | ||||
mean (SD) | 8.0 (11) | 7.1 (9) | 18.8 (11.2) | 8.7 (7.4) |
median (IQR) | 5 (10) | 5 (10) | 20 (25) | 6.3 (5) |
range (mg) | 0–50 | 0–37.5 | 2.5–31 | 2.5–37.5 |
Performance status | ||||
mean (SD) | 3.4 (0.9) | 3.3 (1) | 3.4 (0.9) | 3.5 (0.5) |
median (IQR) | 4 (1) | 4 (IQR 1) | 4 (1) | 4 (1) |
Reported pain mechanism n (%) | 71 (76) | 37 (80) | 10 (77) | 25 (53) |
Mixed nociceptive and neuropathic pain | 47 (66) | 26 (70) | 6 (60) | 18 (72) |
Nociceptive pain | 19 (27) | 6 (16) | 2 (20) | 4 (16) |
Neuropathic pain | 5 (7) | 5 (14) | 2 (20) | 3 (12) |
Malignant diagnoses n (%) | ||||
Gastrointestinal (other than pancreas) | 25 (27) | 12 (26) | 3 (23) | 9 (26) |
Lung | 19 (21) | 11 (23) | 5 (38) | 6 (18) |
Urogenital (other than prostate) | 11 (12) | 6 (13) | 2 (15) | 4 (12) |
Pancreas | 7 (8) | 2 (4) | 2 (6) | |
Breast | 7 (8) | 3 (6) | 3 (9) | |
Hematological | 5 (5) | 3 (6) | 1 (8) | 2 (6) |
Prostate | 2 (2) | 1 (2) | 1 (3) | |
Head and neck | 2 (2) | 1 (2) | 1 (3) | |
Skin | 1 (1) | 1 (2) | 1 (8) | |
Other/unknown origin | 6 (6) | 3 (6) | 1 (8) | 2 (6) |
Non-malignant diagnoses n (%) | ||||
lung fibrosis | 2 (2) | 2 (4) | 2 (6) | |
COPD | 2 (2) | |||
Heart failure | 2 (2) | |||
Renal failure | 1 (1) | 1 (2) | 1 (3) | |
Stroke | 1 (1) | 1 (2) | 1 (3) | |